MAGNOLIA | BGB-3111-214

Zanubrutinib•MZL•Phase 2•Completed
CLINICALTRIALS.GOV DOWNLOAD CLINICAL TRIAL DATA

Summary

This is a single arm study to evaluate the efficacy, safety and tolerability of zanubrutinib (BGB-3111) in participants with relapsed/refractory marginal zone lymphoma (R/R MZL).

Study ArmPopulationInterventionComparisonOutcome

R/R MZL

Zanubrutinib

None

Primary Endpoint: ORR (IRC)


Key Secondary Endpoints: ORR (INV), DoR, PFS, OS, TTR

Study design

Phase II MAGNOLIA trial design in relapsed/refractory marginal zone lymphoma showing eligibility criteria, zanubrutinib treatment, study endpoints, and follow up.

Related Content

CLINICAL TRIAL

BGB-3111-215

ZANUBRUTINIB•B-CELL MALIGNANCIES•PHASE 2•COMPLETED
FIND OUT MORE
CLINICAL TRIAL

ALPINE | BGB-3111-305

ZANUBRUTINIB•CLL/SLL•PHASE 3•COMPLETED
FIND OUT MORE
CLINICAL TRIAL

ROSEWOOD | BGB-3111-212

ZANUBRUTINIB•FL•PHASE 2•COMPLETED
FIND OUT MORE

You are now leaving the website

This link is provided for information purposes only. You’ll be leaving beonemedaffairs.com and accessing a third-party website over which [BeOne Medicines | GmbH] has no control or influence.

This link will take you to a third-party website outside of beonemedaffairs.com.

[BeOne Medicines | GmbH] has no control over this website and makes no representations regarding its content or availability in your location. [BeOne Medicines | GmbH] declines any responsibility for third-party information, data usage policies, or personal data processing.

By proceeding, you acknowledge that you are part of the intended audience of the third-party website and confirm your compliance with applicable laws.

Do you want to leave beonemedaffairs.com

You are now leaving the the website beonemedaffairs.com and entering another BeOne website with different terms of use. Information included on this website may not be specific to your country. Click Continue to proceed